Invesco Ltd. Acquires 550,246 Shares of Cencora, Inc. (NYSE:COR)

Invesco Ltd. lifted its stake in Cencora, Inc. (NYSE:COR - Free Report) by 20.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,243,531 shares of the company's stock after buying an additional 550,246 shares during the quarter. Invesco Ltd. owned approximately 1.68% of Cencora worth $728,757,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of COR. JFS Wealth Advisors LLC grew its position in shares of Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares in the last quarter. SBI Securities Co. Ltd. purchased a new position in Cencora during the 4th quarter valued at approximately $30,000. Kentucky Trust Co bought a new stake in Cencora in the 4th quarter worth approximately $33,000. Householder Group Estate & Retirement Specialist LLC raised its holdings in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock worth $33,000 after acquiring an additional 69 shares in the last quarter. Finally, WASHINGTON TRUST Co boosted its position in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after acquiring an additional 46 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Cencora Trading Up 1.9 %

Shares of COR traded up $5.31 during mid-day trading on Friday, reaching $284.46. 1,509,188 shares of the company's stock traded hands, compared to its average volume of 1,509,347. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. The stock's 50-day moving average is $260.27 and its two-hundred day moving average is $245.16. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $296.65. The stock has a market cap of $55.16 billion, a P/E ratio of 40.46, a P/E/G ratio of 1.31 and a beta of 0.55.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Research analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were given a $0.55 dividend. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 annualized dividend and a yield of 0.77%. Cencora's dividend payout ratio (DPR) is 31.29%.

Insiders Place Their Bets

In related news, EVP Silvana Battaglia sold 5,000 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $242.24, for a total value of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares of the company's stock, valued at $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $269.51, for a total value of $3,928,916.78. Following the sale, the chairman now directly owns 317,913 shares of the company's stock, valued at approximately $85,680,732.63. This trade represents a 4.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,675 shares of company stock worth $8,034,778 in the last three months. Corporate insiders own 10.80% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on COR shares. JPMorgan Chase & Co. boosted their price target on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Bank of America boosted their target price on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday. Evercore ISI increased their price target on shares of Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a report on Thursday, February 6th. Wells Fargo & Company boosted their price objective on Cencora from $251.00 to $274.00 and gave the stock an "equal weight" rating in a research note on Friday, March 14th. Finally, StockNews.com raised Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat, Cencora presently has an average rating of "Moderate Buy" and an average target price of $284.20.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.